Votrient (pazopanib) — United Healthcare
Thyroid carcinoma (follicular, oncocytic, papillary, medullary)
Preferred products
- Caprelsa (vandetanib)
- Cometriq (cabozantinib)
Initial criteria
- For follicular, oncocytic, or papillary carcinoma: (Unresectable locoregional recurrent disease OR persistent disease OR metastatic disease) AND (symptomatic disease OR progressive disease) AND (disease refractory to radioactive iodine treatment OR distant metastatic disease not amenable to radioactive iodine treatment)
- OR for medullary carcinoma: progressive disease OR symptomatic disease with distant metastases AND history of failure, contraindication, or intolerance to one of the following: Caprelsa (vandetanib), Cometriq (cabozantinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Votrient therapy
Approval duration
12 months